Inclusion Criteria:

- Histologically confirmed squamous cell carcinoma (with biopsy on the primary and / or
lymph node metastases) of the oral cavity, oropharynx, hypopharynx, larynx
supraglottix;

- Locally advanced disease, defined by one of the following criteria: any T, N +, M0
(excluding T1, N1), T3-4, N0, M0;

- Not cancer nasopharynx or paranasal sinuses or salivary glands;

- General conditions and associated diseases which does not allow to perform
chemotherapy or radiotherapy in a radical view;

- No other surgical treatments, chemotherapy or radiotherapy for cancer of head and
neck or elsewhere, except non-melanoma skin cancer or in situ cervical cancer and
other solid tumors for which radical treatment has been completed > three years prior
to enrollment in the study and for which the patient has remained continuously free
of disease;

- Accessibility to follow-up;

- Signing of informed consent;

- Interval between examinations of local staging and randomization, maximum 3 weeks

- Interval between randomization and initiation of treatment, maximum 2 weeks

Exclusion Criteria:

- Age <18 years

- ECOG performance status > 0-1

- Hemoglobin <9 g / dL

- Counts of granulocytes, total <1.5 x 10 ^ 9 / L

- Platelet count <100 x 10 ^ 9 / L

- Bilirubin> 1.5 times upper limit of normal (ULN)

- AST or ALT> 3 times ULN

- Creatinine clearance > 50 mL/min

- Mg > 0.5 mmol/L

- Pregnancy or lactation

- Presence of allergy to study drug or to the excipients used in their formulation

- Peripheral neuropathy ≥ grade 2 (CTCAE v3.0)

- Hearing loss / tinnitus ≥ grade 3 (CTCAE v3.0)

- One of the following conditions:

- Myocardial infarction within 12 months prior to randomization

- Severe congestive heart failure

- Unstable angina

- Cardiomyopathy in act

- Ventricular arrhythmia

- uncontrolled hypertension

- Severe psychotic disorders in act

- Severe infection in act

- Any other serious illness that could interfere with the administration of the
therapy provided by the protocol